SetPoint Medical, headquartered in Valencia, California, is developing neuromodulation therapies for patients with inflammatory autoimmune diseases, such as rheumatoid arthritis (RA), inflammatory bowel disease (IBD), psoriasis, diabetes, heart disease, and multiple sclerosis. SetPoint’s proprietary neuromodulation platform consists of an implantable “microregulator”, wireless charger and iPad prescription pad application.
Today EnteroMedics recorded revenue for the first time since it was incorporated nearly eight years ago. The company reported revenue of about $123,000 in the first quarter of the year from the sale of its Maestro RC implantable vagus nerve stimulation system for treating obesity. Revenue was generated through sales by its distribution partner in Australia.
BioControl Medical, Ltd. was founded in 1999 by Yossi Gross, and is based in Yehud, Israel. BioControl’s first devices were developed to treat incontinence due to overactive bladder, stress, and interstitial cystitis. In 2006 American Medical Sytems acquired an exclusive license for the use of the technology in urology, gynecology and other pelvic health applications.
CCC is one of the oldest pacemaker manufacturers in the world. It was founded in 1969 by Dr. Orestes Fiandra, who performed the first succesful, human, long-term pacemaker implant in the world. This was achieved in Uruguay on February 2, 1960 by Dr. Orestes Fiandra and Dr. Roberto Rubio. The pacemaker was manufactured by Dr. Rune Elmqvist of
MicroTransponder was founded in Dallas, TX in 2007 when it licensed technology developed at University of Texas in Dallas (UTD) by Larry Cauller, who heads the cortical connections lab. The first wireless transponder was developed under a DARPA Revolutionizing Prosthetics grant to create a bi-directional neural interface for a prosthetic hand.
EnteroMedics Inc. was founded in St. Paul, MN in 2002 to develop a platform for vagus-nerve stimulation, primarily for obesity management. In March 2011 EnteroMedics received the CE Mark for its second-generation system – the Maestro RC. The EnteroMedics Maestro RC device delivers VBLOC® vagal blocking therapy to through laparoscopically implanted leads to intermittently block the vagus nerves using
In June 2011, Israeli neuromodulation systems developer BioControl Medical spun-off CerebralRx to market its FitNeS vagus nerve stimulation system for the treatment of refractory epilepsy. The FitNes system employs platform technology developed for the CardioFit® system for treating congestive heart failure (HF). CerebralRx spun out of BioControl Medical to expand the use of this technology outside of cardiology for the
Cyberonics was founded in Houston, TX in 1987 to develop an implantable device for the treatment of epilepsy. In July 1997, The FDA approved the VNS Therapy System (formerly known as the NCP® NeuroCybernetic Prosthesis System) as an adjunctive epilepsy treatment for adults and children over 12 years of age with partial onset seizures refractory to
Yossi Gross (born February 5, 1947) is an Israeli medical device innovator and entrepreneur. His medical-device companies are incubated through Rainbow Medical. Currently, the following companies led by Yossi Gross are focusing on active implantable medical devices: BetaStim, developing a new neurostimulation treatment for diabetes Brainsgate, developing an implantable device for acute stroke treatment and brain